Literature DB >> 9407438

Glomerulosclerosis, arteriosclerosis, and vascular graft stenosis: treatment with oral heparinoids.

G E Striker1, E Lupia, S Elliot, F Zheng, C McQuinn, C Blagg, S Selim, J Vilar, L J Striker.   

Abstract

At present there is no known treatment for established glomerulosclerosis or atherosclerosis. Since the principal lesion in glomerulosclerosis involves mesangial cells, a vascular smooth muscle cell, we searched for new therapeutic approaches affecting vascular smooth muscle function, especially with respect to modifying the turnover of extracellular matrix. We used mice transgenic for bovine growth hormone (bGH), since these mice develop end-stage renal disease due to progressive glomerulosclerosis. We previously showed that the subcutaneous injection of a non-anticoagulant heparin reduced glomerulosclerosis in bGH mice. Since injectable drugs are not a practical means of controlling glomerulosclerosis in humans, we assessed oral heparin-like compounds and found that oral pentosan polysulfate (PPS) reduced glomerulosclerosis in bGH mice at non-toxic doses. Because the positive therapeutic response in the bGH model could have been principally hormone-mediated, we examined other models of non-immune mediated glomerulosclerosis, including ROP Os/+ non-diabetic and diabetic mice. We found that an oral PPS (Elmiron), which is approved for other indications in humans, reduced sclerosis in all of these forms of chronic, progressive glomerulosclerosis. Based on the similarity of the cellular events in glomerulosclerosis and arteriosclerosis, we assessed the effect(s) of PPS in congenital (Watanabe rabbits) and induced (New Zealand White lipid-fed rabbits) models of arteriosclerosis. The extent and severity of the lesions was significantly reduced in both models by PPS treatment. Finally, we asked whether the proliferative and sclerotic lesion, which is the cause of vascular graft stenosis, might also respond to PPS treatment. To do this we cultured cells from the materials removed from stenotic arteriovenous grafts in hemodialysis patients. We found that PPS inhibits the proliferation and matrix production in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407438

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  5 in total

1.  Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice.

Authors:  Sheetal A Thakur; Abraham Nyska; Kimber L White; Matthew J Smith; Wimolnut Auttachoat; Dori R Germolec
Journal:  Food Chem Toxicol       Date:  2014-03-20       Impact factor: 6.023

2.  Pentosan polysulfate treatment preserves renal autoregulation in ANG II-infused hypertensive rats via normalization of P2X1 receptor activation.

Authors:  Zhengrong Guan; Barry S Fuller; Tatsuo Yamamoto; Anthony K Cook; Jennifer S Pollock; Edward W Inscho
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-03

3.  Pentosan polysulfate inhibits atherosclerosis in Watanabe heritable hyperlipidemic rabbits: differential modulation of metalloproteinase-2 and -9.

Authors:  Enrico Lupia; Feng Zheng; Fabrizio Grosjean; Ivan Tack; Sophie Doublier; Sharon J Elliot; Helen Vlassara; Gary E Striker
Journal:  Lab Invest       Date:  2011-10-31       Impact factor: 5.662

4.  Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

5.  Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice.

Authors:  Fabrizio Grosjean; Elena M Yubero-Serrano; Feng Zheng; Vittoria Esposito; Shobha Swamy; Sharon J Elliot; Weijing Cai; Helen Vlassara; Fadi Salem; Gary E Striker
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.